Clinical Research
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2006; 12(16): 2549-2555
Published online Apr 28, 2006. doi: 10.3748/wjg.v12.i16.2549
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Immunohistochemical staining of lymph node micrometastasis with the monoclonal antibody CAM 5. 2. A: Micrometastasis consisting of a single cell (original magnification, × 200). B: Micrometastasis consisting of a small cluster of tumor cells (original magnification, × 100).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Survival curves after resection for hilar bile duct carcinoma according to the presence of lymph node metastasis, including micrometastasis.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Survival curves after resection for hilar bile duct carcinoma according to the presence of lymph node metastasis: patients without lymph node metastasis versus those with overt lymph node and micro metastasis.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Survival curves after resection for hilar bile duct carcinoma according to the presence of lymph node metastasis: patients without lymph node metastasis and those with lymph node micrometastasis versus those with overt lymph node metastasis.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Immunohistochemical staining of primary tumors with VEGF-C polyclonal antibody. A: VEGF-C positive (original magnification, × 400). B: VEGF-C-negative (original magnification, × 200).